6 Recommendations for further research
6.1 The Committee considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. This may provide important information about patient subgroups that should be targeted with the different treatments first-line. The Committee was aware that several trials were ongoing that explored treatment sequences relating to vemurafenib and ipilimumab and considered that these would be important. The Committee encouraged patient recruitment to these trials.
6.2 Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.